Introduction: Chemotherapy-induced peripheral neurotoxicity (CIPN) affects nearly 70% of cancer patients after chemotherapy, causing sensory, motor, autonomic dysfunction, and neuropathic pain. The Desirability of Outcome Ranking (DOOR) framework is proposed as a better way to assess preventive or therapeutic interventions for CIPN. Methods: A survey was conducted among Italian healthcare professionals and researchers affiliated to the Italian Chapter of the International Association for the Study of Pain (AISD) to identify the most important outcomes in clinical management and research. Results: Among the 73 respondents, 61 qualified for the survey, with an overall response rate of 1.2%. The vast majority were physicians (77%), most of who...
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting co...
Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication due to treatment with man...
Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity...
To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by ...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
This review provides an update on the current clinical and preclinical understanding of chemotherapy...
This review provides an update on the current clinical and preclinical understanding of chemotherapy...
Purpose: The aim of this study is to examine and compare with the validated, paper/pencil European O...
PURPOSE: Up to 40% of cancer patients treated with neurotoxic chemotherapies experience chemotherapy...
Background and Objective There is no agreement on the gold standard for detection and grading of che...
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent neurologic complicatio...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major and potentially dose-limiting adverse e...
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting co...
Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication due to treatment with man...
Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity...
To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by ...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as on...
This review provides an update on the current clinical and preclinical understanding of chemotherapy...
This review provides an update on the current clinical and preclinical understanding of chemotherapy...
Purpose: The aim of this study is to examine and compare with the validated, paper/pencil European O...
PURPOSE: Up to 40% of cancer patients treated with neurotoxic chemotherapies experience chemotherapy...
Background and Objective There is no agreement on the gold standard for detection and grading of che...
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent neurologic complicatio...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major and potentially dose-limiting adverse e...
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting co...
Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication due to treatment with man...
Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity...